🚫FDA Issues 5-Year Debarment Order Against Evan Asher Field
The Food and Drug Administration (FDA) is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) debarring Evan Asher Field for a period of 5 years from importing or offering for import any drug into the United States. FDA bases this order on a finding that Mr. Field was convicted of one felony count under Federal law. The factual basis supporting Mr. Field's conviction, as described below, is conduct relating to the importation into the United States of a drug or controlled substance. Mr. Field was given notice of the proposed debarment and was given an opportunity to request a hearing to show why he should not be debarred. As of April 25, 2024 (30 days after receipt of the notice), Mr. Field had not responded. Mr. Field's failure to respond and request a hearing constitutes a waiver of his right to a hearing concerning this matter.
Learn More💉National Vaccine Injury Compensation Program Petitions Received
HRSA is publishing this notice of petitions received under the National Vaccine Injury Compensation Program (the Program), as required by the Public Health Service (PHS) Act, as amended. While the Secretary of HHS is named as the respondent in all proceedings brought by the filing of petitions for compensation under the Program, the United States Court of Federal Claims is charged by statute with responsibility for considering and acting upon the petitions.
Learn More💻NIH Office of AIDS Research Advisory Council Meeting Notice
The Department of Health and Human Services announces a virtual meeting of the Office of AIDS Research Advisory Council to discuss key reports and strategic plans related to HIV research. The meeting will be accessible to the public, allowing stakeholders to participate and provide input on the agenda items.
Learn More💊FDA Revokes Emergency Use Authorizations for Specific Drug Products
The Food and Drug Administration (FDA) is announcing the revocation of the Emergency Use Authorizations (EUAs) (the Authorizations) issued to Fresenius Medical Care North America (Fresenius) for multiFiltrate PRO System and multiBic/multiPlus solutions (EUA 048), and to Baxter Healthcare Corp. (Baxter) for REGIOCIT (EUA 068). FDA revoked the Authorizations on January 16, 2025, under the Federal Food, Drug, and Cosmetic Act (FD&C Act). The revocations, including an explanation of the reasons for the revocations, are reprinted in this document.
Learn More🏥HRSA's Proposed Information Collection for HIV/AIDS Program Activities
In compliance with the requirement for opportunity for public comment on proposed data collection projects of the Paperwork Reduction Act of 1995, HRSA announces plans to submit an Information Collection Request (ICR), described below, to the Office of Management and Budget (OMB). Prior to submitting the ICR to OMB, HRSA seeks comments from the public regarding the burden estimate, below, or any other aspect of the ICR.
Learn More🧬Executive Order 14292
Executive Order 14292 focuses on improving the safety and security of biological research in the U.S. It addresses the risks associated with dangerous gain-of-function research, emphasizing the need for stricter oversight, accountability, and compliance measures to protect public health and national security while maintaining the U.S. leadership in biotechnology and health research.
Learn More🧠Proclamation of National Mental Health Awareness Month 2025
The proclamation by the President recognizes May 2025 as National Mental Health Awareness Month, calling for awareness and support for individuals facing mental health challenges. It highlights the administration's commitment to improving mental health care accessibility and encourages dialogue and compassion in addressing these issues.
Learn More💉FDA Meeting on 2025-2026 COVID-19 Vaccine Formula
The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Vaccines and Related Biological Products Advisory Committee. The general function of the committee is to provide advice and recommendations to FDA on regulatory issues. The committee will meet in an open session to discuss and make recommendations on the selection of the 2025-2026 Formula for COVID-19 vaccines for use in the United States. FDA is establishing a docket for public comment on this document.
Learn More💉Overview of National Vaccine Injury Compensation Program Impact
HRSA is publishing this notice of petitions received under the National Vaccine Injury Compensation Program (the Program), as required by the Public Health Service (PHS) Act, as amended. While the Secretary of HHS is named as the respondent in all proceedings brought by the filing of petitions for compensation under the Program, the United States Court of Federal Claims is charged by statute with responsibility for considering and acting upon the petitions.
Learn More🏥Amended Notice of Partially Closed Meeting by NIH
The notice announces a change in the format and schedule of the National Advisory Council on Minority Health and Health Disparities meeting, which will now be entirely virtual rather than hybrid. This meeting is partially closed to the public, highlighting its confidential nature.
Learn More